Global Leukocytapheresis Device Market to Showcase Vigorous Demand during the Pe

Posted by Arslan on December 28th, 2018

Conventional therapy to treat inflammatory bowel diseases such as pharmacotherapy involves substantial adverse effects and the chance of recurrence is more. Leukocytapheresis therapy overcomes such problem which drives the market of leukocytapheresis devices. Increasing prevalence of inflammatory bowel diseases is the prominent factor responsible for the growth of Leukocytapheresis Device Market. Leukocytapheresis therapy mainly involves adult patients therefore growing elderly population responsible for the robust the growth of leukocytapheresis devices market. Leukocytapheresis therapy is more expensive than conventional therapy which degrades the leukocytapheresis devices market growth over forecast period. Furthermore, lack of awareness among patients in the under developing economies may deter the growth of leukocytapheresis devices market.

Leukocytapheresis, also known as white blood cells removal is therapy to reduce the number of white blood cells in the bloodstream. White Blood Cells (leukocytes) are the part of immune system. They help the body to fight infections. There are three types of leukocytes which are involved in the inflammation of bowels. They are granulocytes, monocytes, and lymphocytes. It was found that inflammatory bowel disease is caused by the release of various cytokines from white blood cells, resulting in inflammation of the bowel. Ulcerative colitis and Crohn’s disease are the most chronic inflammatory bowel diseases. Leukocytapheresis is a method helps at ameliorating symptoms in patients with severe inflammatory bowel disease. In leukocytapheresis therapy, the leukocytes involved in inflammation are removed from the blood using extracorporeal treatment unit. During therapy, blood is pumped from the vein of arm or leg through leukocyte removal filter and leukocyte-reduced blood is returned in the body through opposite vein. Leukocytapheresis aims to reduce the number of leukocytes that are involved in inflammation to dampen the inflammatory reaction. According to the Crohn's and Colitis Foundation, 1.6 million Americans are affected yearly with inflammatory bowel disease.

Excellent clinical efficacy of Cellsorba and Adacolumn increases the growth of leukocytapheresis devices market in Japan and other regions. The effectiveness and safety of leukocytapheresis therapy over conventional therapy increases the leukocytapheresis devices market growth in the overall forecast period. Leukocytapheresis therapy has adverse side effects, simple extracorporeal procedure, requires approximately lesser time compared to conventional therapy.  

Request Full Report with TOC: https://www.factmr.com/report/1113/leukocytapheresis-device-market

The above all factors increases the wide adoption of leukocytapheresis therapy worldwide and hence increases the overall market growth. Favorable reimbursement policies allows the growth of leukocytapheresis devices market in low economic regions.

Geographically, global leukocytapheresis devices market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding China and Japan, China, Japan, Middle East and Africa. Currently, Japan is the leading market of leukocytapheresis devices because of leading manufacturers in this region. This is followed by North America due to higher adoption among the patients and technological advancement. Moreover, increase in geriatric population also increase the market growth in this region. Europe held the third position in leukocytapheresis devices market due to increase in healthcare expenditure per capita. Asia Pacific region has been expecting the growth in near future due to increase in the patient’s pool. Middle East Asia and Africa show the delayed growth due lack of awareness in these region hinders the growth of leukocytapheresis devices market.

Some of the key players involve in the leukocytapheresis devices market includes:  Asahi Kasei Medical Co., Ltd., JIMRO Co. Ltd. are some of the leading manufacturers of leukocytapheresis devices.